Decision making process in oncology practice: is the information available and what should it consist of?

  • Tredaniel J
  • Blay J
  • Goldwasser F
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


In terms of systemic chemotherapy, the oncologist is often faced with the difficulty to discriminate between several options, at least according to evidence-based medicine. The aim of the present report was to assess to what extent the efficacy-related parameters required for the decision making process are reported in clinical trials. The analysis was restricted to lung, breast, colorectal and ovarian cancers. It included 135 phase II trials published in 1999, and 79 phase III trials published between 1991 and 2000. Response duration was mentioned in one-half and one-fourth of phases II and III trials, respectively. Only one-half of the trials reported time to progression (TTP). Finally, 28% of phase II and 44% of phase III trials reported RR, TTP and progression rates. The study indicates that the information available from reported clinical trials needs to be upgraded and homogenised in order to improve the decision making process in oncology.

Author-supplied keywords

  • Clinical Trials as Topic
  • Decision Making
  • Disease Progression
  • Disease-Free Survival
  • Humans
  • Neoplasms
  • Remission Induction
  • Survival Rate
  • drug therapy
  • standards
  • statistics & numerical data

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Jean Tredaniel

  • Jean-Yves Blay

  • Francois Goldwasser

  • Bernard Asselain

  • Serge Koscielny

  • Cecile de Labareyre

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free